Johnson & Johnson (JNJ) — closed signal from November 8, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on February 6, 2026.
Predicted vs. what happened
What happened
Reached its target in 13 days.
The thesis — published November 8, 2025
J&J's share price looks beaten down, and investor mood is turning more positive. The FDA cleared DARZALEX Faspro for a high-risk early form of multiple myeloma, a real product win that could spark a short-term bounce. Drug pricing headlines may keep nerves high, but over the next 0-3 months strong drug makers often steady as the story becomes clearer. Start near today's price range and add only if the stock begins rising in a calmer, steadier way.
Primary drivers
- Stock has dropped a lot recently, which often precedes a quick snap-back move
- New FDA approval can draw fresh interest and lift demand in the near term
- Well-run drug company that often recovers after sharp declines in its shares
- Drug pricing news could unsettle investors and cause short-term ups and downs
How it played out
JNJ: target reached in 13 days
Lyra published JNJ at $185.39 on 2025-11-08 with a short-term view for 10% growth. The thesis pointed to a recent drop in the stock, more positive investor mood, FDA clearance for DARZALEX Faspro in high-risk early multiple myeloma, and the chance that drug-pricing headlines could keep trading uneven.
Inside the window, the stock reached the $202.65 target in 13 days. It kept rising after that. The peak was $240.94 on 2026-02-06, with a 30% peak gain, and the window ended at $239.99. The published thesis played out.
What happened during the window
On 2026-01-21, MarketWatch reported that Johnson & Johnson posted $24.6 billion in fourth-quarter revenue and guided to $100.5 billion in 2026 revenue. The same report said oncology sales topped $25 billion in 2025.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.